Harmony Biosciences Holdings, Inc.

HRMY Healthcare Biotechnology

Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.

Revenue
+12.3%
EPS
−6.24%
Free cash flow
−29.4%
Total debt
−11.5%

Quarter to September 2026, against a year earlier

33.04 0.57 +1.76%
Market cap
$1.9B
P/E
10.7×
Fwd P/E
9.9×
Dividend yield
—
F-score
5/9
Altman Z
5.23
Beneish M
−2.99
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
4 4 4 5

+8 more TTM periods

ROE
18.73% 20.46% 17.86% 20.75%
ROA
13.30% 14.61% 12.51% 13.98%
ROIC
30.45% 29.70% 27.66% 50.40%
Return on Tangible Assets
26.93% 31.24% 25.93% 24.23%
Average Days of Receivables
47.13 42.21 43.93 40.68
Free Cash Flow per Share
5.53 6.13 5.91 6.05
Free Cash Flow
323.04 355.08 341.97 347.89
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026